1 Value Stock for Long-Term Investors and 2 Facing Challenges

Barchart·04/03/2026 05:34:16

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. That said, here is one value stock with strong fundamentals and two climbing an uphill battle.

Two Value Stocks to Sell:

Disney (DIS)

Forward P/E Ratio: 13.9x

Founded by brothers Walt and Roy, Disney (NYSE:DIS) is a multinational entertainment conglomerate, renowned for its theme parks, movies, television networks, and merchandise.

Why Do We Think DIS Will Underperform?

1. Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 9.5% over the last five years was below our standards for the consumer discretionary sector
2. Operating margin of 14.8% falls short of the industry average, and the smaller profit dollars make it harder to react to unexpected market developments
3. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital

Disney is trading at $96.58 per share, or 13.9x forward P/E. Read our free research report to see why you should think twice about including DIS in your portfolio.

Royalty Pharma (RPRX)

Forward P/E Ratio: 9.3x

Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself.

Why Does RPRX Worry Us?

1. Sales stagnated over the last two years and signal the need for new growth strategies
2. Smaller revenue base of $2.38 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy

At $48.00 per share, Royalty Pharma trades at 9.3x forward P/E. Dive into our free research report to see why there are better opportunities than RPRX.

One Value Stock to Watch:

Snap (SNAP)

Forward EV/EBITDA Ratio: 9.2x

Founded by Stanford University students Evan Spiegel, Reggie Brown, and Bobby Murphy, and originally called Picaboo, Snapchat (NYSE: SNAP) is an image centric social media network.

Why Do We Like SNAP?

1. Excellent EBITDA margin of 10.6% highlights the efficiency of its business model, and its profits increased over the last few years as it scaled
2. Incremental sales over the last three years have been highly profitable as its earnings per share increased by 27.9% annually, topping its revenue gains
3. Free cash flow margin grew by 6.2 percentage points over the last few years, giving the company more chips to play with

Snap’s stock price of $4.67 implies a valuation ratio of 9.2x forward EV/EBITDA. Is now a good time to buy? Find out in our full research report, it’s free.

Stocks We Like Even More

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.